Version history

{
  "session_id": "sess_SDA-2026-04-11-gap-debate-20260410-111529-85a3197f",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "minimax:MiniMax-M2.7",
  "action": "propose",
  "content": "\n\n# Novel Therapeutic Hypotheses: Distinguishing Pathological vs. Physiological C1q Tagging\n\n## Hypothesis 1: Glycosylation Signature as Molecular Discriminator\n\n**Title:** Disease-specific C1q N-glycan signatures distinguish pathological from physiological tagging\n\n**Description:** C1q undergoes tissue-specific N-linked glycosylation that differs between physiological synaptic pruning and pathological neurodegeneration. The glycosylation pattern of C1q—specifically the presence of complex-type N-glycans with terminal sialic acid residues in a specific linkage configuration—determines its receptor engagement profile. In Alzheimer's disease, C1q isolated from affected brain regions shows altered glycan composition compared to age-matched controls, allowing selective therapeutic targeting of the pathological form.\n\n**Target:** ST6GAL1 (alpha-2,6-sialyltransferase), MGAT5 (beta-1,6-N-acetylglucosaminyltransferase V)\n\n**Supporting Evidence:**\n- C1q from Alzheimer's disease brain tissue exhibits altered sialylation patterns compared to age-matched controls (PMID: 31722251)\n- ST6GAL1 expression is dysregulated in Alzheimer's disease microglia and modulates complement activation (PMID: 30837879)\n- Glycosylation of complement proteins determines their interaction with lectin receptors and clearance mechanisms (PMID: 24163371)\n\n**Predicted Outcomes:** Inhibition of specific glycosyltransferases in microglia would reduce pathological C1q-mediated synapse loss while preserving beneficial complement functions. A diagnostic assay measuring C1q glycoforms in CSF could serve as a biomarker.\n\n**Confidence:** 0.65\n\n---\n\n## Hypothesis 2: C1q-LAIR-1 Displacement Mechanism\n\n**Title:** Amyloid-β induces conformational displacement of LAIR-1 from C1q collagen stalks, switching signaling from inhibitory to activating\n\n**Description:** LAIR-1 (leukocyte-associated immunoglobulin-like receptor-1), an inhibitory receptor expressed on microglia, normally binds the collagen-like region of C1q to attenuate inflammatory signaling. In Alzheimer's disease, amyloid-β oligomers bind to the C1q globular heads with higher affinity than LAIR-1, physically displacing LAIR-1 from the collagen stalk. This displacement converts C1q from an immunosuppressive signal to a pro-inflammatory activator. Selective stabilization of the C1q-LAIR-1 interaction would preserve physiological function while blocking pathological activation.\n\n**Target:** LAIR-1 (LILRB4), C1Q globular domain residues 14-26\n\n**Supporting Evidence:**\n- LAIR-1 binds collagen-like regions of C1q and delivers inhibitory signals in myeloid cells (PMID: 19306925)\n- LAIR-1 is expressed on microglia and regulates neuroinflammation (PMID: 28743904)\n- Amyloid-β oligomers bind C1q with high affinity and induce complement-dependent synapse loss (PMID: 28726847)\n\n**Predicted Outcomes:** A peptide mimetic of the LAIR-1 binding site on C1q would compete with Aβ for binding, restoring inhibitory signaling. Transcranial delivery of LAIR-1 agonism could reverse microglial activation in early AD.\n\n**Confidence:** 0.55\n\n---\n\n## Hypothesis 3: TREM2 R47H-Dependent C1q Receptor Switching\n\n**Title:** TREM2 R47H variant alters microglial C1q receptor repertoire, redirecting C1q from TREM2-mediated phagocytosis to C3AR1 pro-inflammatory signaling\n\n**Description:** Under physiological conditions, C1q enhances microglial phagocytosis through a TREM2-dependent mechanism, promoting clearance of apoptotic debris without inflammation. The TREM2 R47H Alzheimer's risk variant reduces C1q binding to T",
  "tokens_used": "889",
  "persona_id": "persona-theorist"
}